Rituximab vs Cyclophosphamide Induction Therapy for Patients With Granulomatosis With Polyangiitis.

Date publication

novembre 2022

Journal

JAMA network open

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BONNOTTE Bernard

Tous les auteurs :
Puéchal X, Iudici M, Perrodeau E, Bonnotte B, Lifermann F, Le Gallou T, Karras A, Blanchard-Delaunay C, Quéméneur T, Aouba A, Aumaître O, Cottin V, Hamidou M, Ruivard M, Cohen P, Mouthon L, Guillevin L, Ravaud P, Porcher R, Terrier B,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36441554

Résumé

Results of randomized clinical trials have demonstrated rituximab's noninferiority to cyclophosphamide as induction therapy for antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV), with neither treatment having a specific advantage for granulomatosis with polyangiitis (GPA). However, post hoc analysis results have suggested that rituximab might be more effective than cyclophosphamide in inducing remission in patients with proteinase 3-positive AAV.

Mots clés

Male, Humans, Middle Aged, Rituximab, therapeutic use, Peroxidase, Antibodies, Antineutrophil Cytoplasmic, Myeloblastin, Granulomatosis with Polyangiitis, drug therapy, Induction Chemotherapy, Cyclophosphamide, therapeutic use, Coloring Agents

Référence

JAMA Netw Open. 2022 11 1;5(11):e2243799